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Thymoma is derived from epithelial cells of the thymus andthe most common tumor of anterior mediastinum. It has
long been confused with thymic carcinoid but has been
regarded as a histologically distinct entity since 1972.1 Re-
cently developed immunohistochemical method makes it pos-
sible to detect the neuroendocrine character of carcinoma and
reveals that neuroendocrine differentiation is a common fea-
ture of thymic carcinoma.
Although thymic carcinomas often contain tumor cells
having a neuroendocrine feature, thymomas with neuroendo-
crine differentiation are extremely rare. Thymoma can be
accompanied with various diseases but rare with hyperpara-
thyroidism. Herein, we report a case of atypical thymoma
(WHO type B3) with neuroendocrine differentiation com-
bined with hyperparathyroidism with a review of literature.
CASE REPORT
A 54-year-old man was admitted to our hospital be-
cause of incidentally found anterior mediastinal mass on
medical examination before a month. He had no clinical signs
and no familial history.
The laboratory data on admission were as follows:
phosphorous 3.1 mg/dl (2.5–5.5 mg/dl), calcium 11.1 mg/dl
(8.0–10.8 mg/dl), parathyroid hormone (PTH) level was
increased as 140.6 pg/ml (15–65 pg/ml). Computerized to-
mography (CT) scanning showed a 43 mm sized mass
having irregular margin with slightly enhancing soft tissue
mass on anterior mediastinum (Figure 1). Neck CT scan
showed 0.7 cm sized well-defined mildly enhancing solid
nodule indicating parathyroid adenoma.
We performed CT-guided percutaneous needle biopsy
on anterior mediastinal mass. Histologically, tumor cells were
polygonal shape having the round or elongated nuclei with
prominent nucleoli. They had a few intraepithelial lympho-
cytes and formed sheets (Figure 2A). On immunohistochem-
ical stain, the tumor cells were strong positive for synapto-
physin (Figure 2B), weak positive for chromogranin, but
negative for PTH stain (Figures 2C).
We diagnosed of atypical thymoma (WHO [the World
Health Organization] type B3, Masaoka stage II) with neu-
roendocrine differentiation combined with hyperparathyroid-
ism. Radical thymectomy was performed (Figure 2D), and
adjuvant radiotherapy was done. CT scan followed by 6
months after operation showed no recurrence of the tumor,
and he has been under outpatient follow-up.
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FIGURE 1. Chest CT-scan showing 43-mm sized mediasti-
nal mass having irregular margined, slightly high density,
with slightly enhancing soft tissue mass on anterior mediasti-
num. CT, computed tomography.
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DISCUSSION
The histologic classification of thymoma has remained
a subject of controversy for many years, until WHO commit-
tee published a histologic typing system of thymic tumor in
1999. They divided thymoma into four categories on the basis of
the morphology and the lymphocyte to epithelial cell ratio.
Among them, type B3 thymoma (atypical thymoma) is com-
posed of round or polygonal epithelial cells mixed with a minor
component of lymphocytes, resulting in a sheet-like growth of
the neoplastic epithelial cells2 and has a malignant behavior.
It is used to be thought that neuroendocrine tumors in
many organs were of neural crest origin, but the origin of
many neuroendocrine tumors is now thought to be epithelial
cells or primitive cells that have capacity for bidirectional
differentiation toward both nonneuroendocrine and neuroen-
docrine cell.3 Synaptophysin is believed to be a specific and
reliable marker of neuroendocrine differentiation, and the
finding of this marker in a thymic epithelial neoplasm is by
itself a strong indicator of malignancy. Thymic neuroendo-
crine tumor must be regarded malignant lesion that is prone
to metastasis even after total excision. More aggressive man-
agement, including adjuvant chemotherapy and radiotherapy,
might result in increased survival.
Another clinical issue about our case is the combined
hypercalcemia. We ruled out ectopic secretion based on two
reasons. First, parathyroid hormone stain on tumor cell was
negative. Second, serum PTH level did not decrease after
thymectomy.
Although there had been reports about association be-
tween thymic carcinoid and multiple endocrine neoplasia
(MEN) since 1972, our case did not fulfill the diagnostic
criteria of MEN1,4 which is defined as the presence of two of
the three main MEN1 tumor types (parathyroid adenomas,
enteropancreatic endocrine adenomas, and pituitary adeno-
mas). So, we considered the parathyroid adenoma was an
incidental finding and not related to the thymoma. In addition,
serum calcium level was less than 1.0 mg/dl (0.25 mmol/liter)
above the upper limit of normal range, creatinine clearance
was within normal range, and he was older than 50 years;
therefore, we decided to observe parathyroid adenoma. Fur-
ther supporting theory that MEN1 is related to thymic carci-
noid on the base of genetic background has been postulated
and also increasing number of MEN1-related thymic carci-
noids came to our attention.5 Thus, we must bear in mind
screening for MEN1 in patients with thymic tumor with
neuroendocrine feature.
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FIGURE 2. A, H&E staining, tumor
cells are polygonal, medium to large
sized, and have the prominent nucle-
oli. There are a few intraepithelial lym-
phocytes forming sheets. B, Immuno-
histochemical stain, the tumor cells
are strong positive for synaptophysin.
C, Negative for parathyroid hormone
stain on immunohistochemical stain.
D, Cut surface of the tumor, grossly,
there is a grayish white, ill defined,
and lobulating mass. It is composed
of firm mass with fibrous septum and
infiltrates into the surrounding mediasti-
nal fat. H&E, hematoxylin and eosin.
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